Brief: Cantargia Reports Updated Encouraging Survival Data From Canfour Trial

Cantargia AB

29/12/2021 13:29

Dec 29 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA REPORTS UPDATED ENCOURAGING SURVIVAL DATA FROM
CANFOUR
TRIAL WITH NADUNOLIMAB AND CHEMOTHERAPY IN PANCREATIC CANCER
    * UPDATED DATASET FROM INITIAL 33 PATIENTS ELIGIBLE FOR
EFFICACY
ANALYSIS CONTINUE TO SHOW STRONGER RESULTS THAN EXPECTED FROM
CHEMOTHERAPY ONLY
    * MEDIAN SURVIVAL IS 12.7 MONTHS, MEDIAN IMMUNE
PROGRESSION-FREE
SURVIVAL (IPFS) IS 7.2 MONTHS, AND 1-YEAR SURVIVAL RATE IS 55%
    * FURTHERMORE, 40 ADDITIONAL PDAC PATIENTS ARE INVESTIGATED
IN AN
EXTENSION OF CANFOUR TRIAL
    * RESULTS FROM THIS PART OF TRIAL ARE EXPECTED TO MATURE FOR
PRESENTATION DURING H1 2022
    * SAFETY AND RESPONSE RATES ARE SIMILAR TO PREVIOUS UPDATE
FROM
MAY 2021
    * CANTARGIA IS CURRENTLY PREPARING FOR A RANDOMIZED AND
POTENTIALLY PIVOTAL TRIAL IN FIRST LINE PANCREATIC CANCER
    * DESIGN AND TIMELINES WILL BE DISCLOSED ONCE PREPARATORY
DISCUSSIONS WITH MAJOR REGULATORY AUTHORITIES HAVE BEEN
CONCLUDED

Source text for Eikon:  ID:nWkr1P1nxp 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))